SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial

(2014) Takashi Sasaki et al.   ADVANCES IN THERAPY

Expression of SLC2A9 Isoforms in the Kidney and Their Localization in Polarized Epithelial Cells

(2014) Toru Kimura et al.   PLoS One

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate

(2013) Takeo Nakanishi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Functional Cooperation of SMCTs and URAT1 for Renal Reabsorption Transport of Urate

(2012) Yang Lu et al.   Drug Metabolism and Pharmacokinetics

Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2

(2012) Atsushi Hosomi et al.   PLoS One

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

(2011) K Yamamoto et al.   BRITISH JOURNAL OF PHARMACOLOGY

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients

(2010) Lei Yu et al.   HUMAN GENETICS

Uric acid transport and disease

(2010) Alexander So et al.   JOURNAL OF CLINICAL INVESTIGATION

(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment

(2010) Hiroyuki Kakinuma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients

(2009) G. Zoppini et al.   DIABETES CARE

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations

(2009) Melanie Kolz et al.   PLoS Genetics

Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13)

(2008) Andrew Bahn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans

(2008) Naohiko Anzai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

(2008) Veronique Vitart et al.   NATURE GENETICS

Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey

(2008) H. K. Choi et al.   RHEUMATOLOGY

SLC2A9 Is a High-Capacity Urate Transporter in Humans

(2008) Mark J Caulfield et al.   PLOS MEDICINE